Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Chs (CHSCN) Cash & Equivalents (2016 - 2025)

Chs' Cash & Equivalents history spans 16 years, with the latest figure at $374.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 16.83% year-over-year to $374.7 million; the TTM value through Nov 2025 reached $374.7 million, down 16.83%, while the annual FY2025 figure was $327.8 million, 58.76% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $374.7 million at Chs, up from $327.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.8 billion in Q3 2023 and bottomed at $211.9 million in Q1 2022.
  • The 5-year median for Cash & Equivalents is $423.2 million (2021), against an average of $573.8 million.
  • The largest annual shift saw Cash & Equivalents soared 193.28% in 2021 before it plummeted 68.9% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $310.0 million in 2021, then soared by 105.26% to $636.3 million in 2022, then surged by 112.13% to $1.3 billion in 2023, then plummeted by 66.62% to $450.5 million in 2024, then fell by 16.83% to $374.7 million in 2025.
  • Per Business Quant, the three most recent readings for CHSCN's Cash & Equivalents are $374.7 million (Q4 2025), $327.8 million (Q3 2025), and $323.9 million (Q2 2025).